<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04282746</url>
  </required_header>
  <id_info>
    <org_study_id>CR108751</org_study_id>
    <secondary_id>54135419EDI1002</secondary_id>
    <secondary_id>2019-004129-25</secondary_id>
    <nct_id>NCT04282746</nct_id>
  </id_info>
  <brief_title>A Study of Sublingually Administered (S)-Ketamine Oral Solution in Healthy Participants</brief_title>
  <official_title>An Open-label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Sublingually Administered (S)-Ketamine Oral Solution in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the plasma pharmacokinetic (PK) profile
      following the single ascending dose (SAD) levels of an (S)-ketamine oral solution for
      sublingual administration in healthy participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2020</start_date>
  <completion_date type="Anticipated">August 18, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Concentrations of (S)-ketamine</measure>
    <time_frame>Predose, 1 minute (min), 3 min, 5 min, 10 min, 15 min, 30 min, 40 min, 1 hour (h), 1.5h, 2h, 3h, 4h, 6h, 8h, 12h and 24h postdose</time_frame>
    <description>Observed plasma concentrations of (S)-ketamine will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentrations of Nor-(S)-ketamine</measure>
    <time_frame>Predose, 1 minute (min), 3 min, 5 min, 10 min, 15 min, 30 min, 40 min, 1 hour (h), 1.5h, 2h, 3h, 4h, 6h, 8h, 12h and 24h postdose</time_frame>
    <description>Observed plasma concentrations of nor-(S)-ketamine will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Vital Sign Abnormalities</measure>
    <time_frame>Up to 4 Weeks</time_frame>
    <description>Number of participants with vital signs (heart rate [HR], systolic blood pressure [SBP], diastolic blood pressure [DBP]) abnormalities will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to 4 Weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product does not necessarily have a causal relationship with the treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>JNJ-54135419</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of JNJ-54135419-AAA oral solution for sublingual administration in 1 of 3 serial dose escalating cohorts in fasted conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-54135419</intervention_name>
    <description>Single dose of JNJ-54135419 oral solution will be administered sublingually.</description>
    <arm_group_label>JNJ-54135419</arm_group_label>
    <other_name>(S)-ketamine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) between 20.0 and 28.0 kilogram per meter square kg/m^2 inclusive
             (BMI = weight/height^2) with a minimum weight of 60 kilogram (kg) and a maximum of 100
             kg

          -  Participant must be healthy based on clinical laboratory tests performed at screening.
             If the results of the serum chemistry panel, hematology or urinalysis are outside the
             normal reference ranges, retesting of an abnormal lab value that may lead to exclusion
             will be allowed once during the screening phase

          -  Non-smoker (not smoked for 3 months prior to screening)

          -  A woman must have a negative serum beta-human chorionic gonadotropin (beta-hCG) at
             screening and a negative urine pregnancy test prior to dosing on Day 1

          -  A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted
             reproduction during the study and for at least 1 month after the last study drug
             administration

        Exclusion Criteria:

          -  Cardiac arrhythmias or other cardiac disease, hematological disease, hypertension,
             lipid abnormalities, respiratory disease, diabetes mellitus, renal or hepatic
             insufficiency, thyroid disease, Parkinson's disease, infection, glaucoma, epilepsy or
             any other illness that the Investigator considers should exclude the participant

          -  Positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies
             or human immunodeficiency virus (HIV) antibodies at screening visit

          -  Drinks, on average, more than 5 cups of tea/coffee/cocoa or 8 cans of cola per day

          -  Clinically significant acute illness within 7 days prior to study drug administration

          -  Donation of 1 or more units (approximately 450 milliliter [mL]) of blood or acute loss
             of an equivalent amount of blood within 90 days prior to study drug administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>SGS Life Science Services</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108751</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 21, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2020</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

